imatinib mesylate has been researched along with Ischemic Stroke in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrae, J; Betsholtz, C; Dang, ST; Enomoto, A; Fujikawa, M; Fujimori, T; Hamashima, T; Ishii, Y; Maki, T; Mori, H; Nguyen, HN; Nguyen, QL; Nguyen, VT; Okuno, N; Sasahara, M; Takao, K; Yamamoto, S | 1 |
| Campos-Gazeau, F; Chalayer, E; De Broucker, T; Denier, C; Groh, M; Guidoux, C; Hamidou, M; Hunault, M; Kahn, JE; Lefèvre, G; Lyoubi, A; Meunier, R; Muron, T; Rohmer, J; Sène, D; Slama, B; Tennenbaum, J; Venditti, L | 1 |
2 other study(ies) available for imatinib mesylate and Ischemic Stroke
| Article | Year |
|---|---|
Vascular PDGFR-alpha protects against BBB dysfunction after stroke in mice.
Topics: Animals; Blood Vessels; Blood-Brain Barrier; Collagen Type I; Hemorrhage; Imatinib Mesylate; Immunoglobulin G; Infarction, Middle Cerebral Artery; Ischemic Stroke; Matrix Metalloproteinase 9; Mice, Knockout; Receptor, Platelet-Derived Growth Factor alpha; Stroke; Transforming Growth Factor beta1 | 2021 |
FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
Topics: Adult; Brain; Cerebral Infarction; Coronary Thrombosis; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Ischemic Stroke; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retrospective Studies; Treatment Outcome | 2021 |